GlassScriptPhysician profile
Rosemary Mcgrath
NPI 1710947148
$959.14
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $570 · 2020: $362 · 2021: $27.14.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $172.17 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $164.11 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.46 | 2019-2020 | |
| Pfizer INC. | $138.87 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $133.02 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.46 | 2019 | |
| Glaxosmithkline, LLC. | $31.73 | 2020 | |
| Amarin Pharma, INC. | $28.76 | 2019 | |
| Abbvie INC. | $27.14 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $20.26 | 2019 | |
| Merck Sharp & Dohme LLC | $16.59 | 2019 | |
| Bausch Health US, LLC | $14.07 | 2020 | |
| Lilly USA, LLC | $12.50 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosemary Mcgrath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.